Caspofungin
Acute Myeloid Leukemia By FAB Classification
Explore 16 assets in Acute Myeloid Leukemia By FAB Classification →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia By FAB Classification
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Caspofungin (this asset) | Children's Oncology Group | P3 | BB · 64 |
| Daunomycin | Wake Forest University Health Sciences | P3 | BBB |
| Idarubicin | University of Nebraska | P3 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BB |
| Valspodar | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | Roswell Park Cancer Institute | P3 | BB |
| Azacitidine | guomei | P2 | BB |
| Fluconazole | Children's Oncology Group | P3 | BB |
| Midostaurin | Mayo Clinic | P2 | B |
+41 more in the Acute Myeloid Leukemia By FAB Classification cohort
Other indications for Caspofungin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fungal Infectious Disease | — | P4 | BBB · 77 |
| Acute Monocytic Leukemia | — | P3 | BB · 64 |
| Adult Acute Monocytic Leukemia | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DaunomycinWake Forest University Health SciencesBBB
- IdarubicinUniversity of NebraskaBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- ValspodarNational Cancer Institute (NCI)BB
- Mercaptopurine AnhydrousRoswell Park Cancer InstituteBB
Citation
Floatz Terminal. Caspofungin in Acute Myeloid Leukemia By FAB Classification. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/caspofungin-acute-myeloid-leukemia-by-fab-classification
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →